Cynosure Group LLC Makes New Investment in Bristol Myers Squibb Company $BMY

Cynosure Group LLC acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,475 shares of the biopharmaceutical company’s stock, valued at approximately $565,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. State Street Corp boosted its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the period. Geode Capital Management LLC boosted its stake in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $1,947,272,000. Finally, Primecap Management Co. CA boosted its stake in shares of Bristol Myers Squibb by 12.6% during the 4th quarter. Primecap Management Co. CA now owns 24,875,550 shares of the biopharmaceutical company’s stock worth $1,341,787,000 after purchasing an additional 2,781,230 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $56.30 on Tuesday. The stock has a market cap of $114.97 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a 50-day moving average of $57.67 and a two-hundred day moving average of $56.99.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 8th. HSBC lifted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Barclays assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.